Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cost of Revenue (2017 - 2020)

Ironwood Pharmaceuticals' Cost of Revenue history spans 7 years, with the latest figure at $897000.0 for Q4 2020.

  • For Q4 2020, Cost of Revenue fell 91.86% year-over-year to $897000.0; the TTM value through Dec 2020 reached $3.1 million, down 86.86%, while the annual FY2020 figure was $3.1 million, 86.86% down from the prior year.
  • Cost of Revenue for Q4 2020 was $897000.0 at Ironwood Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $21.5 million in Q4 2018 and bottomed at $506000.0 in Q3 2019.
  • The 4-year median for Cost of Revenue is $3.8 million (2017), against an average of $5.6 million.
  • The largest annual shift saw Cost of Revenue skyrocketed 390.96% in 2018 before it crashed 91.86% in 2020.
  • A 4-year view of Cost of Revenue shows it stood at $9.0 million in 2017, then soared by 138.9% to $21.5 million in 2018, then crashed by 48.69% to $11.0 million in 2019, then plummeted by 91.86% to $897000.0 in 2020.
  • Per Business Quant, the three most recent readings for IRWD's Cost of Revenue are $897000.0 (Q4 2020), $2.2 million (Q1 2020), and $11.0 million (Q4 2019).